Brilinta significantly reduced rate of composite of stroke and death in THALES trial
This was a statistically significant and clinically meaningful reduction. Furthermore, aspirin plus Brilinta significantly reduced the rate of the first secondary endpoint of ischaemic stroke by 21%, compared